GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Total Current Liabilities

BioNTech SE (BSP:B1NT34) Total Current Liabilities : R$11,063 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. BioNTech SE's total current liabilities for the quarter that ended in Dec. 2023 was R$11,063

BioNTech SE Total Current Liabilities Historical Data

The historical data trend for BioNTech SE's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Total Current Liabilities Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 630.00 3,792.81 22,246.44 16,395.21 11,063.29

BioNTech SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16,395.21 8,648.84 9,565.42 9,525.31 11,063.29

BioNTech SE Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

BioNTech SE's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4699.426+150.147
+Other Current Liabilities+Current Deferred Liabilities
=4325.93+1887.786
=11,063

BioNTech SE's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=4699.426+150.147
+Other Current Liabilities+Current Deferred Liabilities
=4325.93+1887.786
=11,063

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

BioNTech SE Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BSP:B1NT34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (BSP:B1NT34) » Definitions » Total Current Liabilities
Comparable Companies
BGNE ALNY MRNA BMRN RPRX LEGN INCY UTHR SRPT TECH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB
Traded in Other Exchanges
BNTX:USA BNTX:Mexico 0A3M:UK 22UA:Germany BNTX:Austria
Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
Website
https://www.biontech.de
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

BioNTech SE (BSP:B1NT34) Headlines

No Headlines